Try our Advanced Search for more refined results

Novartis Pharmaceuticals v. Accord Healthcare, Inc.

  1. September 29, 2022

    High Court Halts Generic Gilenya As Novartis Appeals IP Loss

    The U.S. Supreme Court has blocked for now the mandate of a recent Federal Circuit decision that a Novartis Pharmaceuticals patent covering multibillion-dollar multiple sclerosis drug Gilenya is invalid.

  2. September 27, 2022

    Fed. Circ. Won't Halt Gilenya Generics During Novartis Appeal

    The Federal Circuit on Tuesday declined Novartis Pharmaceuticals' request to stay the mandate in the court's recent decision that the patent covering multibillion-dollar multiple sclerosis drug Gilenya is invalid while the company seeks U.S. Supreme Court review.

  3. September 20, 2022

    Fed. Circ. Won't Eye Novartis Case Flipped By Judge Change

    The full Federal Circuit said Tuesday it won't review a decision in which a split panel initially upheld Novartis' patent on multibillion-dollar multiple sclerosis drug Gilenya, then invalidated it after a different judge joined the panel.

  4. August 05, 2022

    Profs Urge Full Fed. Circ. To Review 'Startling' Novartis Ruling

    Two groups of law professors have urged the full Federal Circuit to review a case in which a split panel initially sided with Novartis in January and upheld its patent on multibillion-dollar multiple sclerosis drug Gilenya, but then invalidated it after a different judge joined the panel.

  5. July 22, 2022

    Full Fed. Circ. Urged To Undo 'Extraordinary' Gilenya IP Ruling

    Novartis on Thursday urged the Federal Circuit to reverse what it called "an extraordinary" ruling invalidating its patent covering its multibillion-dollar multiple sclerosis drug Gilenya, arguing that a judge's departure from the Federal Circuit bench led to an "unprecedented" and flawed ruling against the drugmaker.

  6. June 21, 2022

    Fed. Circ. Reverses Initial Panel To Find Gilenya IP Invalid

    The Federal Circuit held Tuesday that Novartis' patent covering its multibillion-dollar multiple sclerosis drug Gilenya isn't valid after all, reversing an earlier panel that found in favor of the Swiss drugmaking giant.

  7. February 25, 2022

    Generic-Drug Maker Takes Novartis Battle To Full Fed. Circ.

    A Chinese generic-drug maker wants the full Federal Circuit to take a look at a splintered appeals court ruling that allowed Novartis to maintain its monopoly on a multibillion-dollar multiple sclerosis drug for even longer by adding dosage specifications to an older patent covering the drug.

  8. January 04, 2022

    Split Fed. Circ. Affirms Novartis' Grip On Gilenya

    The Federal Circuit signed off on a Delaware federal court's decision that Novartis' patent on its multibillion-dollar multiple sclerosis drug had an adequate written description, in a split decision that the court's dissenting chief judge warned would "dramatically" expand the ability of drug companies to broaden what their patents cover.

  9. July 08, 2021

    Fed. Circ. Appears Split On Novartis' MS Drug Patent

    The Federal Circuit wasn't in agreement Thursday about the strength of one of the patents covering Novartis' blockbuster multiple sclerosis drug Gilenya, with two of the panel judges at times using the assembled attorneys as a medium to argue with each other.

  10. July 01, 2021

    Fed. Circ. Forecast: Kite Takes Aim At Juno's $1.2B IP Win

    The Federal Circuit next week will hear Kite Pharma's appeal of a $1.2 billion verdict in favor of Juno Therapeutics in a case over a cancer treatment patent, marking the first time the appeals court will hear a case in-person since the start of the pandemic. Here's a look at that case — plus all the other major patent cases facing the court in the coming week.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!